Vancomycin Hydrochloride

CHEMBL1200628 Phase 4 Disetujui Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
1485.7 g/mol
LogP
Phase
4

A hydrochloride salt form of vancomycin with the same therapeutic properties. This powerful glycopeptide antibiotic is used intravenously to treat serious bacterial infections caused by gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA), and is taken orally specifically to treat Clostridioides difficile (C.

Berat Molekul

1485,7000 g/mol

TPSA

530,00 Ų

Area Terapeutik

Mekanisme Kerja

Glycopeptide antibiotic inhibiting cell wall synthesis by binding D-Ala-D-Ala terminus of peptidoglycan precursors.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanisme

Glycopeptide antibiotic inhibiting cell wall synthesis by binding D-Ala-D-Ala terminus of peptidoglycan precursors.

Struktur 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O.Cl

InChI

InChI=1S/C66H75Cl2N9O24.ClH/c1-23(2)12-34(71-5)58(88)76-49-51(83)26-7-10-38(32(67)14-26)97-40-16-28-17-41(55(40)101-65-56(54(86)53(85)42(22-78)99-65)100-44-21-66(4,70)57(87)24(3)96-44)98-39-11-8-27(15-33(39)68)52(84)50-63(93)75-48(64(94)95)31-18-29(79)19-37(81)45(31)30-13-25(6-9-36(30)80)46(60(90)77-50)74-61(91)47(28)73-59(89)35(20-43(69)82)72-62(49)92;/h6-11,13-19,23-24,34-35,42,44,46-54,56-57,65,71,78-81,83-87H,12,20-22,70H2,1-5H3,(H2,69,82)(H,72,92)(H,73,89)(H,74,91)(H,75,93)(H,76,88)(H,77,90)(H,94,95);1H/t24-,34+,35-,42+,44-,46+,47+,48-,49+,50-,51+,52+,53+,54-,56+,57+,65-,66-;/m0./s1

Molecular Formula

C66H76Cl3N9O24

HBD / HBA

20 / 26

Ikatan yang Dapat Dirotasi

13

Atom Berat

102

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

A hydrochloride salt form of vancomycin with the same therapeutic properties. This powerful glycopeptide antibiotic is used intravenously to treat serious bacterial infections caused by gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA), and is taken orally specifically to treat Clostridioides difficile (C.

Glycopeptide antibiotic inhibiting cell wall synthesis by binding D-Ala-D-Ala terminus of peptidoglycan precursors.

Yes, Vancomycin Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200628. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 6420023. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.